Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Show more

Location: 700 Quince Orchard Road, Gaithersburg, MD, 20878, United States | Website: https://www.novavax.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.304B

52 Wk Range

$5.01 - $15.22

Previous Close

$8.03

Open

$8.02

Volume

6,101,403

Day Range

$8.02 - $8.50

Enterprise Value

920.4M

Cash

612.3M

Avg Qtr Burn

-157.7M

Insider Ownership

8.76%

Institutional Own.

58.19%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

Approved

Update

Approved

Update

Approved

Update

Phase 3

Data readout

Phase 3

Update

Phase 2

Update

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued